Zdrowie i gospodarka · 27/01/2020

FDA Releases Final Guidance on Minimal Residual Disease for Hematologic Malignancies

The FDA has issued a final guidance to help sponsors use minimal residual disease as a biomarker in clinical trials for treating specific hematologic malignancies, following inconsistent quality of MRD data in marketing applications.